However, first-generation FLT3 inhibitors can target downstream of FLT3 and may also be effective in parallel signaling and in other targets in AML at diagnosis, which is characterized by the coexistence of multiple leukemic clones [25,26]. This evidence concerns the gene FLT3 and acute myeloid leukemia.